Abstract:Background 18 F-florzolotau positron emission tomography (PET) assists in the in vivo diagnosis of progressive supranuclear palsy (PSP). Objective We aimed to investigate the relationship between 18 F-florzolotau uptake and clinical severity, structural volume changes, and plasma markers in four-repeat tauopathies. Methods A total of 80 participants were recruited: 35 with PSP (11 with PSP-Richardson syndrome and 24 with PSP non-Richardson syndrome), 9 with corticobasal syndrome (CBS), 10 with Alzheimer's disease (AD), 8 with Parkinson's disease, and 18 controls. All participants underwent 18 F-florzolotau PET, brain magnetic resonance imaging (MRI), and plasma biomarker investigation (total and phosphorylated tau [pTau181], neurofilament light chain, and glial fibrillary acidic protein [GFAP]). Results 18 F-Florzolotau uptake was significantly higher in the subcortical regions of the pallidum, subthalamic nucleus (STN), midbrain, red nucleus, and raphe nucleus in PSP patients compared to the other groups (all p < 0.01). Subcortical tau tracer retention assisted in distinguishing PSP and CBS from controls (AUC = 0.836, p < 0.001). Tau tracer retention could differentiate PSP and CBS from AD in cortical ( p < 0.001) and subcortical regions ( p = 0.028). The motor severity of PSP positively correlated with tau burden in STN ( p = 0.044) and substantia nigra ( p = 0.035). Tau tracer uptake was associated with cortical volume changes in CBS ( p = 0.031), PSP non-Richardson syndrome ( p = 0.003), and AD ( p = 0.044). Cortical tau retention correlated with plasma levels of GFAP ( p = 0.001) and pTau181 ( p = 0.036). Conclusions Subcortical 18 F-Florzolotau uptake assist the diagnosis of 4R tauopathy parkinsonism. Additionally, regional tau burden contributes to structural brain volume changes and correlates with plasma levels of GFAP and pTau181.

Subcortical tau burden correlates with regional brain atrophy and plasma markers in four-repeat tauopathy parkinsonism